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Abstract
Giant cell tumor (GCT) of bone is a locally destructive tumor that occurs predominantly in long bones of post-pub-
ertal adolescents and young adults, where it occurs in the epiphysis. The majority are treated by aggressive curet-
tage or resection. Vascular invasion outside the boundary of the tumor can be seen. Metastasis, with identical
morphology to the primary tumor, occurs in a few percent of cases, usually to the lung. On occasion GCTs of bone
undergo frank malignant transformation to undifferentiated sarcomas. Here we report a case of GCT of bone that
at the time of recurrence was found to have undergone malignant transformation. Concurrent metastases were
found in the lung, but these were non-transformed GCT.
Introduction
Giant cell tumor of bone is a locally destructive tumor
that occurs predominantly in long bones of post puber-
tal adolescents and young adults, where it occurs in the
epiphysis. The majority are treated by aggressive curet-
tage or resection. Histologically, giant cell tumor of
bone classically shows many large multinucleated giant
cells with interspersed haphazardly arranged mononuc-
lear cells, and the nuclear features of both elements are
described as similar. Some tumors also have areas with
a fascicular or storiform pattern devoid of giant cells
resembling a benign fibrous histiocytoma. Vascular inva-
sion outside the boundary of the tumor can be seen.
The rate of local recurrence varies among centers and is
influenced by the completeness of surgical treatment,
with high speed burring, adjuvants, and bone cement
adding to the effectiveness of curettage treatment [1].
Unresectable tumors such as large sacral masses can be
treated with radiation [2]. New therapies targeting the
Receptor Activator of NF-B (RANK) signaling pathway,
such as with the anti-RANK ligand antibody denosumo-
mab are in early stages of investigation [3]. Metastasis,
with identical morphology to the primary tumor, occurs
in a few percent of cases, usually to the lung. These
cases are treated with wedge resection with good long
term outlook [4]. On occasion giant cell tumors of bone
undergo frank malignant transformation to undifferen-
tiated sarcomas. Here we report a case of giant cell
tumor of bone that at the time of recurrence was found
to have undergone malignant transformation. Concur-
rent metastases were found in the lung, but these were
non-transformed giant cell tumor. Contemporaneous
histologically benign pulmonary metastases and locally
recurrent giant cell tumor of bone with transformation
to sarcoma has not to our knowledge been previously
reported.
Materials and methods
This study was performed with the approval of the Rush
University IRB, ORA#: 09092501-CA01. The study
included detailed clinical information, imaging and
pathology. Tissue was fixed in 10% buffered formalin at
room temperature and dehydrated and paraffin
embedded in overnight processing. Immunohistochem-
ical stains were performed as follows: The following
antibodies were used on Ventana Benchmark and the
manufacturer’s solution CC1 for antigen retrieval.: CD4
(Biocare Medical, Concord, CA) 1:10 dilution, CD43
(Cell Marque, Rocklin, CA) prediluted, P63 (Fisher
Scientific, Pittsburgh, PA) 1:500. Ki-67 immunostaining
was performed on the Dako autostainer PLUS with
FLEX Envision chemistry using clone MIB-1 (Dako,
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antigen retrieval under pressure in a microwave oven.
Images were captured on an Olympus BX41 microscope
with a Spot Insight color camera with Spot Advanced
software.
Report of a case
A 29 year-old male was diagnosed with a giant cell
tumor of the left proximal tibia at an outside institution
in January 2005. He underwent intralesional curettage
followed by heat cauterization and methacrylation. Eight
months later, in September 2005, the patient had a local
recurrence of the tumor which was treated with cement
removal and repeat curettage followed by argon beam
ablation and repeat cementing.
The patient presented at this institution in June 2009
with severe pain and disability of the left leg at the site
of the previous excisions. Radiographs demonstrated a
large lucency around the cement (Figure 1). Concurrent
staging revealed nodules on chest radiograph, and com-
puterized tomography revealed two nodules in each
lung, up to 2.8 cm in dimension (Figure 2). In July 2009,
the patient underwent bilateral thoracoscopy-assisted
pulmonary resections. Frozen section revealed the pul-
monary lesions to be histologically benign. As a result of
the benign pulmonary histology, a repeat intralesional
excision, cauterization with phenol and methacrylation
with internal fixation of the proximal tibia was per-
formed. Intraoperatively, the tumor was recurrent
throughout (cephalad, caudad, medial and lateral to the
cement) and bulging poster medially to the pes anserine
tendons. Fibrous tissue was observed near the patellar
ligament insertion. The post-operative course was unre-
markable. The permanent paraffin sections confirmed
the benign histology in the lung lesions; however, the
tibial recurrence was frankly malignant. As a result, this
patient received pre-operative chemotherapy given the
poor prognosis [5]. Following the chemotherapy, he was
taken to surgery, and an en-bloc resection of the upper
tibia was performed. He was reconstructed with a mod-
ular oncology tibial and knee prosthesis. No residual
tumor was seen in the resected specimen. Close follow-
up, consisting of chest CT and tibial imaging every
3 months, is ongoing.
Pathological findings
Histological sections of the tumor from presentation
showed classic giant cell tumor of bone with the typical
histological patterns (Figure 3). Most areas showed mul-
tinucleated giant cells admixed with round and spindled
mononuclear cells (A, B). In some areas the spindled
Figure 1 Radiograph of the recurrent left tibial tumor showing
a near circumferential lucency (arrowheads) around the bone
cement (arrow).
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spindled cells proliferated in the absence of giant cells.
No atypia was seen.
The gross specimen from the tibial excision consisted
of fragments of pink-tan and red-brown tissue with
pieces of cement and bone fragments. The metastatic
tumor nodules resected from the lung (Figure 4) grossly
were well circumscribed mahogany nodules and histolo-
gically showed essentially identical morphology to the
original tumor. Some areas of the recurrent tibial tumor
also show classic histology of benign giant cell tumor of
bone (Figure 5A). Immunostains distinguish between the
monocyte lineage cells–both mononuclear cells and mul-
tinucleated giant cells, which are highlighted by the line-
age specific markers CD4 and CD43 (Figure 5B, inset; the
smaller, darker CD43+ cells are T cells) and the stromal
Figure 2 Chest CT showing bilateral metastatic tumor nodules
in the lung bases.
Figure 3 A, B, C and D. The tumor at presentation (2005), showing giant cells admixed with round and spindled mononuclear cells (A, original
magnification ×230, B, original magnification ×800) and areas with predominantly (C, original magnification ×290) and exclusively (D, original
magnification ×250) spindled stromal cells. No atypia was seen.
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the tibial tumor showed undifferentiated pleomorphic
sarcoma having large spindled cells with vesicular nuclei,
p r o m i n e n tn u c l e o l ia n ds c a t t e r e dm i t o s e s( u pt om o r e
than 20 per 10 standard high power fields) and abundant
apoptotic debris (Figure 5C). The benign component
showed nuclear P63 staining in a subset of cells, as has
been reported (Figure 5D) [6]. Also, Mib-1 staining is
low in the benign component and significantly increased
in the malignant component (Figures 5E, F).
Comment and discussion
Giant cell tumors of bone are neoplasms of stromal cells
that recruit a mononuclear population of hematopoietic
origin [7]. These monocytes and/or multinucleated giant
cells may in turn produce factors that support growth of
the stromal cells, but this has not been explored. The
onocytederived component is highlighted in immunohis-
tochemical stains for the lysosomal marker CD68 and
for monocyte lineage specific markers. The lineage of
the stromal cells is still poorly characterized, but a sub-
set variably expresses alkaline phosphatase, similar to
osteoblasts [8]. Factors such as monocyte colony stimu-
lating factor (m-CSF) and RANK ligand, which are
important for osteoclastogenesis and for fusion of
monocytes to form multinucleated giant cells, are
expressed in giant cell tumors of bone [9]. Presumably
the stromal cells are the source of m-CSF, akin to the
situation in localized and diffuse giant cell tumors of
tendon sheath/synovium where m-CSF is overexpressed
by the neoplastic cells, sometimes secondary to a recur-
rent translocation [10,11]. Accordingly, cultured giant
cell tumor stromal cells are chemoattractant to periph-
eral blood monocytes [12].
In karyotypic analysis of giant cell tumors of bone,
end-to-end fusions of various chromosomes, termed
telomeric associations, are seen in most tumors in a
subset of cells, and these have been localized by FISH
studies to the CD68 negative spindled stromal compo-
nent [13]. At lower frequency than telomeric associa-
tions, clonal chromosome gains, deletions and
translocations can also be found in GCT of bone [14].
Translocations occur more frequently in tumors that
have more telomeric associations, and they probably
result from ensuing problems in separation of dicentric
chromosomes during telophase [14]. However, cells with
chromosomal abnormalities do not have enough of a
growth advantage to dominate the tumor population,
and analyses of many metaphases is required to recog-
nize that there are clonal subpopulations in the tumor
[14]. In Goronova’s study [14] there was no association
between karyotype and prognosis. Also, no dominant
recurrent cytogenetic abnormality was seen that might
give clues to pathogenesis. Thus, this peculiar low level
chromosome instability reflects an underlying defect in
chromosome maintenance, though probably not due to
a generalized defect in telomerase activity [15]. The
minor genomic instability seen in vitro is reflected by a
low but definite probability of transformation clinically,
as seen here. However, because of the current lack of a
defined molecular or cytogenetic marker of GCT of
bone, formal proof that the rare cases of malignant
transformation are due to evolution of the spindle cells
of GCT of bone is lacking. An alternative hypothesis
would be that that GCT of bone predisposes to malig-
nancy in an unrelated cell–akin to secondary malig-
nancy in the setting of osteonecrosis or Paget’s disease
of bone. Notably, cases are considered secondary
Figure 4 A and B, Metastatic tumor in a lung wedge resection (2009) grossly showing a well circumscribed mahogany nodule (A),
histologically similar to the original tumor (B original magnification ×290).
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Page 4 of 7Figure 5 A, B, C, D, E and F. Recurrent tibial tumor (2009): area with classic histology of benign giant cell tumor of bone. The nuclei of the two
components are similar, with smooth contours and relatively condensed chromatin (A original magnification ×290). Immunostain for CD4 (B
original magnification ×290) and CD43 (B, inset; the smaller, darker CD43+ cells are T cells original magnification ×290). Area with frank
malignant transformation characterized by large and pleomorphic cells with vesicular and irregularly shaped nuclei, prominent nucleoli and
frequent mitotic figures (C). Immunostain for P63 (D, original magnification ×290). Immunostain for MIB-1 in benign (E) and malignant (F) areas
(original magnification × 145).
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the malignant component is seen.
This case illustrates a sarcoma arising at the site of a
locally recurrent GCT of bone, with concurrent non-sar-
comatous metastases. Local recurrence of GCT of bone
is common, occurring 10-20% of the time [16-18], and
depends on the aggressiveness of the initial surgery [19].
Metastasis with “benign” morphology, most commonly
to the lung, was reported in an average of 3% of cases
(table 1), and more than half occurred in patients who
also had local recurrence.
Diagnosis of transformation relies on overt malignant
cytological features, as necrosis and scattered mitoses
c a nb es e e ni nt h eu s u a l“benign” giant cell tumor of
bone. Immunohistochemical studies are not required for
the diagnosis of transformation. Usually there is no evi-
dent lineage of maturation, but cases of osteosarcoma
have been reported [9,20-24]. The incidence of malig-
nancy in GCT varies considerably among studies, with
an overall rate of approximately 5% considering the lar-
gest series together (table 2). About half were associated
with prior irradiation (table 2), but transformation was
found in the initial resection in about one third of cases
(table 2). Secondary transformation had a latency of up
to 28 years [20] in a case that without radiotherapy.
Given the wide range of reported incidence of malig-
nancy in giant cell tumor of bone among studies, it is
probable that this entity has been over diagnosed in the
reported series. Of note, in the publications with the
highest rates of malignancy, there was no pathological
slide review. In Bertoni’s study, pathological review was
performed [20], and as a result, the initial diagnosis was
revised to something other than malignant
transformation of giant cell tumor in 12 of 26 cases
initially considered for which slides were available.
Anract’s study, which did not include pathological
review, includes 5 cases with “well differentiated fibro-
sarcoma” [5], which is much different from the more
widely recognized high grade transformation. Likewise,
in Domovitov’s report, 57% of the cases had the curious
diagnosis of “focally” malignant histology. Accordingly,
the outcomes in their study were optimistic, with 80%
of patients predicted to be recurrence free at 5 years
based on their data, compared to the 10-50% overall
survival estimated in most other series. Thus, excluding
radiation-induced transformation cases, and considering
only series with pathological review, the incidence of
malignant transformation of giant cell tumor of bone is
only about 1%, which is the rate cited in the WHO pub-
lication [25].
Conclusion
We report here the case of a giant cell tumor of the
proximal tibia of a 29 year old man treated with aggres-
sive curettage that recurred 4 years later with malignant
transformation and “benign” metastases to the lung.
Recurrence, malignant transformation, and metastasis
with “benign” morphology all occur in giant cell tumor
of bone. This is the first report of all three occurring in
as i n g l ep a t i e n t .T h ei n f l u e n c eo fl o c a lr e c u r r e n c eo n
malignant transformation and pulmonary metastases is
largely unknown. Malignant transformation has been
reported most frequently with radiation even in nonre-
current tumors. Similarly, benign pulmonary metastases
have been reported to occur in recurrent and nonrecur-
rent tumors. The current report adds little to the discus-
sion of the fate of locally recurrent giant cell tumor of
bone. The molecular pathways leading to giant cell
tumors of bone are still largely uncharacterized.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in Chief of this Journal.
Table 1 Reported incidence of “benign” metastasis in
giant cell tumor of bone.
# Cases (total) Metastatic (%) Reference#
214 7 [1]
624 14 (2.2) [4]
470 21 (4.5) [26]
Total 1308 42 (3.2)
Table 2 Reported incidence of malignancy associated with giant cell tumor of bone in large published series
# Cases (total) Total Malig (%) 1° (%) 2° (%) Post radiation Reference#
193 29 (15) 17 (9) 9 (5) 3 (2) [5]
924 17 (2) 5 (0.5) 6 (0.5) 6 (0.5) [20]
627 31 (5) ? ? 25 (4) [27] includes cases cited in [21]
195 17 (9) 3 (1.5) 2 (1) 12 (6) [28]
607 13 (2) 6 (1) 7 (1) ? [29]
275 26 (10) ? ? 5 (2) [30]
Total 2821 133 (4.7)
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